Get started
Author

Julie L. Wolf

Effects of Smoking on the Pharmacokinetics of Erlotinib
2006 · Marta Hamilton, Julie L. Wolf, et al. · Clinical Cancer Research · 313
Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys
2000 · Daniel W. Drolet, Joyce Nelson, et al. · Pharmaceutical Research · 206
Overcoming CYP1A1/1A2 Mediated Induction of Metabolism by Escalating Erlotinib Dose in Current Smokers
2009 · Andrew N. Hughes, Mary E.R. O'Brien, et al. · Journal of Clinical Oncology · 144
PDF
Evaluation of the Absolute Oral Bioavailability and Bioequivalence of Erlotinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in a Randomized, Crossover Study in Healthy Subjects
2006 · Paul Frohna, Jianfeng Lu, et al. · The Journal of Clinical Pharmacology · 112
The evaluation of E-Cadherin and vimentin as biomarkers of clinical outcomes among patients with non-small cell lung cancer treated with erlotinib as second- or third-line therapy.
2012 · Frank Richardson, G David Young, et al. · PubMed · 51
Erlotinib plus gemcitabine in patients with unresectable pancreatic cancer and other solid tumors: phase IB trial
2006 · Tomislav Dragovich, Mark Huberman, et al. · Cancer Chemotherapy and Pharmacology · 49
Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of Necuparanib Combined with Nab-Paclitaxel and Gemcitabine in Patients with Metastatic Pancreatic Cancer: Phase I Results
2017 · Eileen M. O’Reilly, James Roach, et al. · The Oncologist · 46
PDF
The effect of rifampicin, a prototypical CYP3A4 inducer, on erlotinib pharmacokinetics in healthy subjects
2014 · Marta Hamilton, Julie L. Wolf, et al. · Cancer Chemotherapy and Pharmacology · 46
An Evaluation of the Toxicities of 2' -Fluorouridine and 2'-Fluorocytidine-HCI in F344 Rats and Woodchucks (Marmota monax)
1999 · Frank C. Richardson, Bud C. Tennant, et al. · Toxicologic Pathology · 34
Randomised phase II trial of gemcitabine and nab-paclitaxel with necuparanib or placebo in untreated metastatic pancreas ductal adenocarcinoma
2020 · Eileen M. O'Reilly, Diletta Barone, et al. · European Journal of Cancer · 33
Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
2006 · Amita Patnaik, Debra Wood, et al. · Clinical Cancer Research · 26
Necuparanib combined with nab-paclitaxel + gemcitabine in patients with metastatic pancreatic cancer: Phase 2 results.
2017 · Eileen Mary O'Reilly, Devalingam Mahalingam, et al. · Journal of Clinical Oncology · 6
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Phase 1 results.
2015 · Eileen Mary O'Reilly, Devalingam Mahalingam, et al. · Journal of Clinical Oncology · 4
Safety Assessment of 4′-Thio- β - d -Arabinofuranosylcytosine in the Beagle Dog Suggests a Drug-Induced Centrally Mediated Effect on the Hypothalamic-Pituitary-Adrenal Axis
2006 · Dorothy B. Colagiovanni, Daniel W. Drolet, et al. · International Journal of Toxicology · 4
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of necuparanib combined with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer: Updated phase 1 results.
2016 · Eileen Mary O'Reilly, Devalingam Mahalingam, et al. · Journal of Clinical Oncology · 2
Abstract #1741: Combination treatment strategy of an IGF-1R kinase inhibitor, OSI-906, in models of progressive disease following initial response to EGFR tyrosine kinase inhibitor therapy
2009 · Eric N. Brown, Stacia Silva, et al. · Cancer Research
Works count: 16
Citation count: 1,076
H-index: 11
I10-index: 11
Year
Topic
Type